Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results.
Diagnosis & Disease Information
Patient Age, Use of Checkpoint Inhibitors in Cancer Linked to COVID-19 Severity
Cancer is among the underlying conditions that increase risk for COVID-19.
Neoadjuvant Nivolumab Appears Promising in Merkel Cell Carcinoma
A small phase 1/2 study shows high pCR rates.
A Call to Investigate IL-17 as Drug Target for Lung Cancer, COVID-19
Interleukin 17 may be a therapeutic target worth investigating for patients with lung cancer and SARS-CoV-2 infection, existing literature suggests.
Exposure to Antibiotics Associated With Survival Detriment in Patients With Advanced Melanoma Treated With ICIs
Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.
Atezolizumab Plus Enzalutamide Fails to Improve Outcomes in mCRPC
Atezolizumab plus enzalutamide failed to improve OS compared with enzalutamide alone among patients with mCRPC in the IMbassador250 trial.
Continuous Dosing of BRAF/MEK Inhibition Superior to Intermittent Dosing in Melanoma
Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.
Durvalumab Plus Olaparib and Chemotherapy Improved pCR in HER2-Negative Breast Cancer
The presenter said “there may be promising activity with olaparib and durvalumab in addition to paclitaxel” in this breast cancer subtype.
Thyroid Dysfunction During Anti–PD‐1 Immunotherapy Linked to Better Survival Outcomes
There was no increase in survival linked to acquired subclinical thyroid dysfunction or preexisting thyroid dysfunction, however.
NBUVB Phototherapy May Not Increase Skin Cancer Risk in Patients With Vitiligo
Many patients with vitiligo undergo multiple courses of phototherapy, which may raise concerns about their risk of photocarcinogenesis.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...